How does Cosentyx (secukinumab) affect the immune system?
Cosentyx is an immunology medicine that targets interleukin-17A (IL-17A). By blocking IL-17A signaling, it reduces inflammation in conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This lowers immune-driven inflammation, but it also changes how the body’s immune system responds to infections.
Because IL-17A is involved in host defense against some infections, people taking Cosentyx may have increased risk of certain infections, and clinicians typically screen for active infection and monitor during treatment.
What infections should people taking Cosentyx watch for?
In people using IL-17 pathway inhibitors, the main patient-facing concern is developing infections while on therapy. If you develop symptoms such as fever, worsening cough, burning with urination, or other signs of infection, contact your clinician promptly.
A common practical issue with IL-17 inhibitors is increased susceptibility to fungal infections, especially mucocutaneous candidiasis (for example, oral or genital yeast infections). If symptoms suggest yeast infection (such as persistent mouth soreness with white patches, or genital itching/discharge), patients should seek medical advice rather than self-treating.
What happens to immunity after stopping Cosentyx?
Cosentyx’s immune effects generally lessen as drug levels fall after discontinuation. However, the timeline varies by individual and dosing schedule. In practice, many patients see their inflammatory disease gradually worsen over time after stopping, which reflects the return of the immune pathway activity that Cosentyx suppresses.
If you are planning surgery, travel, or you’re sick and considering stopping temporarily, discuss it with your prescriber so the timing is coordinated with infection risk and disease control.
Is Cosentyx a “strong” immunosuppressant like chemotherapy or transplant meds?
Cosentyx is an immunomodulator, not chemotherapy. It targets a specific inflammatory pathway (IL-17A) rather than broadly suppressing the entire immune system. That said, it still can affect infection risk, so it’s not “immunology-free.” The right way to think about it is targeted immune pathway suppression with meaningful infection monitoring.
Can you get vaccines while on Cosentyx?
Vaccine guidance depends on the type of vaccine. In general, patients on immune-targeting therapies are often advised to avoid live vaccines unless their clinician specifically approves them. Inactivated vaccines may be used, but optimal timing can depend on disease control and the dosing schedule.
If you’re planning flu/COVID/other immunizations, ask your clinician or pharmacist which vaccines are appropriate for you and whether you need timing adjustments around your dosing.
Are there drug interactions or medical situations that raise infection risk on Cosentyx?
Infection risk can be higher if Cosentyx is combined with other immune-suppressing drugs (for example, certain systemic immunosuppressants or high-dose corticosteroids). It can also be higher if you have chronic infections or serious comorbidities.
Your prescriber will typically consider your infection history (including tuberculosis screening where relevant) and current medications before starting or continuing Cosentyx.
What do patients mean when they ask “Cosentyx and immunity”?
People usually ask this to clarify:
- whether Cosentyx makes them more likely to get infections,
- whether they can fight off illnesses normally while on it,
- what symptoms should trigger a call to the doctor,
- and how vaccination or stopping the drug affects protection.
If you share what prompted your question (a specific infection, upcoming vaccine, or side effect you’re noticing), I can tailor the guidance to that scenario using the same “immunity/infection risk” frame.
Source
[1] DrugPatentWatch.com – Cosentyx (secukinumab) related information: https://www.drugpatentwatch.com/